🧬 Aging Wiki

heart-rate-variability-biomarker

Properties1
aliasesHRV, RMSSD, SDNN, pNN50, heart rate variability

20 min read

Heart Rate Variability (Vital-Sign Biomarker)

Heart rate variability (HRV) is the beat-to-beat fluctuation in the time interval between successive heartbeats (R-R intervals). It is not a molecular clock — the clock-specific frontmatter fields (n-cpgs-or-features, model-architecture, test-retest-icc) are structurally not applicable and are left null, consistent with the vital-sign modality established in schema R55 and implemented in the sibling page resting-heart-rate-biomarker. HRV integrates cardiac autonomic regulation, predominantly reflecting parasympathetic (vagal) tone at rest: higher HRV indicates flexible, responsive autonomic control; lower HRV reflects autonomic rigidity, sympathetic dominance, or impaired vagal withdrawal. Reduced HRV is one of the most robustly replicated predictors of all-cause and cardiovascular mortality across general-population cohorts 1 2 3. It also serves as a tangible, continuously measurable index of autonomic imbalance with aging, linking inflammaging, the cholinergic anti-inflammatory pathway, and cardiovascular aging into a unified organismal-level biomarker 4.

Note on modality: vital-sign: HRV is classified under the vital-sign modality — single-parameter resting physiological measures that index aging/mortality risk. The unit: field does not map cleanly to the schema’s (years | percentile | rate | composite-score) enum; the actual metric units are milliseconds (time-domain) and ms² or normalized units (frequency-domain) — documented in the body. This matches the RHR page’s precedent of storing the real-world unit string directly.

Identity and Measurement

HRV is not a single number but a family of metrics derived from R-R interval time series (typically from ECG or PPG). The 1996 Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology established the canonical measurement standards; the Shaffer & Ginsberg 2017 overview provides a practical reference for all commonly used metrics 5 6.

Time-domain metrics

MetricUnitWhat it indexes
SDNNmsStandard deviation of all normal R-R intervals; reflects total HRV from all sources (sympathetic + parasympathetic + circadian)
RMSSDmsRoot mean square of successive differences; primarily reflects vagal (parasympathetic) tone; robust to breathing rate changes; the most widely used clinical index
pNN50%Percentage of successive R-R intervals differing by >50 ms; highly correlated with RMSSD; also reflects vagal tone
NN50countAbsolute count of successive intervals >50 ms difference

RMSSD is preferred for autonomic aging research because it is dominated by parasympathetic activity, can be computed from short recordings (5 minutes), and tracks well with HF power in the frequency domain. Wearable devices (Oura, Garmin, Apple Watch, Polar) predominantly report RMSSD.

Frequency-domain metrics

MetricFrequency bandUnitWhat it indexes
HF power0.15–0.40 Hzms² (or n.u.)Respiratory sinus arrhythmia (RSA); closely tracks vagal tone; the autonomic component most clearly linked to CAP (see below)
LF power0.04–0.15 Hzms² (or n.u.)Mixed sympathetic + vagal origin; influenced by baroreflex; interpretation contested
LF/HF ratio—dimensionlessOriginally proposed as sympathovagal balance index; now controversial — not a pure sympathetic index
Total power<0.4 Hzms²Overall spectral variance; similar interpretation to SDNN
VLF power0.0033–0.04 Hzms²Influenced by thermoregulation, renin-angiotensin, and slow metabolic oscillations; prognostically significant in long recordings

Key principle: HF/RMSSD index vagal modulation of HR under controlled breathing conditions, but do not directly measure vagal tone — respiration rate changes alone can shift HF power without altering actual vagal output 6. LF/HF ratio should not be interpreted as a simple sympathovagal balance score.

Measurement standards

  • Short-term: 5-minute supine ECG at rest; no recent physical activity, caffeine, food, or emotional stress; standardized breathing optional but recommended for HF power interpretation
  • Long-term (24h Holter): Captures circadian HRV variation; SDNN from 24-h recordings has strong prognostic value; required for VLF analysis
  • Wearable/PPG: Consumer devices estimate RMSSD overnight from PPG; directionally useful for trend monitoring; less accurate than ECG R-R intervals; systematic bias with irregular heart rhythms (atrial fibrillation)
  • Recording context matters: HRV is highly state-dependent (posture, breathing rate, time of day, stress, illness, recovery status) — serial measurements must standardize conditions for longitudinal aging comparisons

HRV declines substantially and progressively with normal aging 7. The primary drivers:

  1. Reduced parasympathetic tone — progressive loss of vagal modulation of the SA node is the dominant mechanism; reflected in declining RMSSD and HF power
  2. Intrinsic sinoatrial node remodeling — fibrosis and pacemaker cell loss reduce the range over which the SA node can be autonomically modulated
  3. Arterial baroreflex impairment — reduced baroreceptor sensitivity attenuates reflex-driven vagal modulation
  4. Increased sympathetic tone — chronic sympathetic overdrive (catecholamine excess; chronic stress, metabolic syndrome, obesity) suppresses vagal activity

Approximate population-level age trend (RMSSD, short-term, healthy adults):

Age decadeMedian RMSSD (approx.)
20s40–55 ms
40s30–40 ms
60s20–30 ms
80+15–25 ms

Values from Nunan 2010 systematic review of normal values; wide inter-individual variation; aerobic fitness is a major modifier 7.

The rate of decline is not uniform: the steepest age-associated HRV reduction occurs in midlife (30–60 years), with some evidence that the rate of decline attenuates in the oldest-old. Sex differences exist — women tend to have higher HF power (vagal tone) than age-matched men across much of adult life, but this advantage narrows post-menopause.

HRV as a Predictor of Mortality and Disease

Tsuji 1994 — Framingham Heart Study (foundational cohort) 1

The first major population study linking reduced HRV to all-cause mortality:

  • n=736 elderly community-dwelling subjects (mean age 72±6 years); Framingham Heart Study; 4-year follow-up
  • Lower HRV (including low-frequency power, which was the strongest predictor in multivariate analysis) was associated with significantly increased all-cause mortality risk
  • Association was independent of traditional cardiovascular risk factors
  • Established the paradigm that autonomic markers predict survival beyond standard clinical variables

Dekker 2000 — ARIC Study 2

Validated the prognostic value of ultra-short HRV recordings in a large, younger general-population sample:

  • Parent cohort n=14,672 (ARIC study; community-dwelling adults aged 45–65); HRV assessed by case-cohort design in a random subsample of ~900 subjects plus all incident CHD cases (395) and deaths (443) through 1993
  • Low SDNN from a 2-minute rhythm strip predicted coronary heart disease incidence and all-cause mortality (e.g., lowest vs. intermediate SDNN tertile all-cause relative risk 1.50–1.51, CVD mortality relative risk 1.98–2.10), independent of traditional cardiovascular risk factors
  • Demonstrated that even very short HRV recordings carry prognostic information — relevant for screening applications

Jarczok 2022 — Systematic review and meta-analysis (primary synthesis reference) 3

The most comprehensive quantitative synthesis of HRV-mortality evidence:

  • 32 studies (37 samples); n=38,008 total participants; includes both healthy populations and patient samples
  • Lower HRV parameter values were significant predictors of higher mortality across all ages, sexes, continents, and populations
  • 5-minute RMSSD, lowest quartile vs. others: combined HR 1.56 (95% CI 1.32–1.85)
  • Associations were comparable across most examined HRV parameters (SDNN, RMSSD, HF power, total power)
DimensionStatus
Pathway conserved in humans?yes — direct human cohort data
Effect conserved across sexes?yes — broadly; some sex differences in magnitude
Replicated in humans?yes — multiple independent cohorts and two meta-analyses

HRV, Inflammaging, and the Cholinergic Anti-Inflammatory Pathway

The mechanistic bridge between HRV and age-related disease risk converges on the vagal cholinergic anti-inflammatory pathway (CAP), and HRV is its most accessible functional readout 4:

  • The vagus nerve tonically suppresses peripheral inflammation by releasing acetylcholine onto alpha-7 nicotinic acetylcholine receptors (α7nAChR, encoded by CHRNA7) on macrophages and other immune cells, inhibiting NF-κB-driven pro-inflammatory cytokine production (IL-1β, IL-6, TNF-α)
  • With aging, reduced vagal tone (measurable as declining HRV) withdraws this tonic anti-inflammatory brake, contributing to the chronic low-grade inflammation that characterizes inflammaging
  • Elevated sympathetic activity with aging creates a reciprocal pro-inflammatory milieu: sympathetic neurotransmitters (norepinephrine) promote macrophage activation; reduced vagal counter-regulation allows the inflammatory signal to amplify
  • This ANS imbalance — sympathetic excess + vagal insufficiency — is now recognized as an upstream driver of multiple aging hallmarks, not merely a correlate 4

Forward links to sibling pages being seeded concurrently:

See also chronic-inflammation for the inflammaging mechanistic context.

Mendelian Randomization Status

mendelian-randomization: partial — rationale: multiple HRV GWAS instruments exist and MR studies have been conducted, but the genetic causal inference for all-cause mortality is negative (phenotypic but not genotypic HRV predicts mortality), while MR evidence for specific cardiovascular endpoints (cardiac arrest, atrial fibrillation) shows selective positive signals. The picture is heterogeneous across endpoints, mirroring the RHR MR finding.

Tegegne 2023 — Communications Biology (GWAS + prospective mortality study) 8

The most direct test of genetically vs. phenotypically predicted HRV mortality:

  • GWAS: n=46,075 European ancestry individuals (UK Biobank); identified 23 genome-wide significant variants in 16 loci (17 independent; 8 novel) for HRV traits
  • Prospective mortality analysis: n=54,312 (separate UK Biobank subsample with phenotypic HRV + mortality follow-up; median 6.99–8.14 years across HRV traits); 1,548 (2.9%) died during follow-up
  • Lower phenotypic HRV was associated with significantly elevated all-cause mortality: per-unit ln(RMSSD) decrease HR 1.19 (95% CI 1.10–1.28; p=1.48×10⁻⁵); per-unit ln(SDNN) decrease HR 1.32 (95% CI 1.23–1.43; p=9.30×10⁻¹²)
  • Genetically predicted HRV was NOT associated with all-cause mortality or cardiovascular mortality (null MR finding — genetic risk scores for HRV not associated with mortality in independent sub-sample n=412,891)
  • Interpretation: measured HRV captures clinically relevant physiological variance beyond genetic architecture — likely fitness, disease burden, and real-time autonomic state. This is the same MR-null-for-mortality pattern seen for RHR in van de Vegte 2023

Zhao 2024 — EJCI (MR: HRV and cardiovascular diseases) 9

  • Two-sample MR using GWAS instruments for SDNN, RMSSD, and pvRSA/HF against cardiovascular outcomes
  • Genetically predicted pvRSA/HF (HF power) was causally associated with increased cardiac arrest risk (OR 2.02, 95% CI 1.25–3.28, p=0.004); no heterogeneity or pleiotropy detected
  • No significant causal associations found for hypertension, heart failure, myocardial infarction, or arrhythmia in general

Geurts 2023 — Clinical Research in Cardiology (HRV, AF, MR) 10

  • Longitudinal population study + two-sample MR in the Rotterdam Study (n=12,334; median follow-up 9.4 years; 1,302 incident AF cases)
  • Observational: higher SDNN (HR 1.24, 95% CI 1.04–1.47, p=0.021) and higher RMSSD (HR 1.33, 95% CI 1.13–1.54, p=0.001) were significantly associated with increased new-onset AF risk; associations driven mostly by women
  • MR results: genetic causal inference supported the HRV → AF association — genetically determined SDNN (IVW OR 1.60, 95% CI 1.27–2.02, p=8.36×10⁻⁵) and RMSSD (IVW OR 1.56, 95% CI 1.31–1.86, p=6.32×10⁻⁷) were significantly associated with increased AF odds, with no heterogeneity or pleiotropy detected
  • Note: higher HRV is associated with AF risk here (not lower, as in most mortality/CVD contexts) — the proposed mechanism involves sinoatrial node dysfunction promoting atrial ectopy and re-entry, not autonomic failure per se

Summary of MR picture:

EndpointObservational HRV effectMR resultConcordant?
All-cause mortalityLower HRV → more deaths (HR ~1.56 per quartile)No MR causal signal 8No
Cardiac arrestLower HRV/HF → elevated riskMR: pvRSA/HF causally associated 9Partial
Atrial fibrillationHigher HRV → more AF (observational; n=12,334 Rotterdam Study)MR: supported — genetically higher SDNN/RMSSD → more AF 10Yes

The MR null for all-cause mortality does not negate HRV as a clinically useful biomarker — it indicates that the mortality association is substantially confounded by fitness, lifestyle, and disease burden, all of which are captured in measured HRV. HRV functions as an integrative fitness-autonomic index rather than a direct causal pathway from autonomic function to death. gap/contradictory-evidence

Intervention Responsiveness

Aerobic exercise training (primary modality)

Physical activity consistently increases resting HRV in controlled trials. The El-Malahi 2024 meta-analysis (systematic review of RCTs and non-RCTs in adults with established cardiovascular disease — CHF, CAD, PAD, or ACS/MI) found that the overall pooled short-term effect on RMSSD was not statistically significant (SMD 0.32, p=0.15; I²=0.69 for RMSSD), but the overall SDNN effect was significant (SMD 0.30, p=0.01; I²=0.00) 11. In the congestive heart failure subgroup, both RMSSD (p=0.01) and SDNN (p=0.02) showed significant improvement with aerobic exercise. For 24-hour assessment, the LF/HF ratio improved (p=0.05) but RMSSD and SDNN (24-h) were not significant. Note: this meta-analysis covers CVD patients only; evidence for HRV augmentation by exercise in healthy older adults is well-supported by cross-sectional literature but extends beyond this particular meta-analysis. Mechanism: aerobic training enhances cardiac vagal tone through multiple pathways — increased stroke volume reduces resting demand, and central autonomic nuclei (nucleus tractus solitarius, dorsal vagal nucleus) increase parasympathetic outflow chronically.

  • Effect appears dose-dependent; continuous aerobic exercise is more consistently effective than high-intensity interval training for resting HRV in older adults
  • Cross-sectional data: lifelong endurance athletes have substantially higher RMSSD than sedentary age-matched controls throughout life

Slow-paced breathing (~6 breaths/min / resonant frequency)

Voluntary slow breathing at approximately 6 breaths/minute (0.1 Hz) maximally entrains the baroreflex, producing large oscillations in heart rate that manifest as strikingly elevated RMSSD and HF power during the practice session. The Laborde 2022 systematic review and meta-analysis (223 studies: 172 assessing HRV during VSB sessions; 16 immediately post-session; 49 multi-session) found consistent increases in vagally-mediated HRV during slow breathing, immediately after sessions, and with sustained multi-session practice 12. This is resonant frequency breathing / heart rate coherence training. The acute session effect is large; the chronic resting-state effect of regular practice on baseline HRV is smaller but present.

Beta-blockers

Beta-1 adrenergic receptor antagonists raise resting HRV by reducing sympathetic chronotropic input and allowing greater vagal expression. The HRV increase from beta-blockade is pharmacologically distinct from exercise-induced HRV elevation: it reflects sympathetic suppression rather than vagal augmentation. Clinically, beta-blockade–induced HRV normalization post-myocardial infarction predicts reduced sudden death risk.

Other interventions

InterventionEffect on HRVStrength of evidence
Yoga / tai chiIncreases RMSSD; comparable to aerobic exercise in some trialsModerate
Biofeedback / resonant breathingAcutely elevates HF power; chronic effect on baseline HRV is smallerModerate
Sleep optimizationPoor/fragmented sleep acutely suppresses HRV; recovery improves itModerate (observational)
Omega-3 supplementationSmall increases in HRV in some meta-analysesWeak
AlcoholAcutely suppresses HRV; chronic moderate alcohol: unclear long-term HRV effectModerate

Hallmark Linkage

HallmarkConnection
chronic-inflammationReduced vagal tone (low HRV) withdraws the cholinergic anti-inflammatory brake (CAP), allowing NF-κB-driven inflammaging; reciprocally, chronic inflammation suppresses vagal activity — bidirectional amplification loop 4
mitochondrial-dysfunctionCardiac autonomic control requires mitochondrially replete neurons in dorsal vagal nucleus and nucleus ambiguus; mitochondrial dysfunction in autonomic neurons may reduce vagal output, depressing HRV
cellular-senescenceSenescent cells secrete SASP components (IL-6, IL-1β, TNF-α) that suppress parasympathetic tone; preliminary evidence links senescent-cell burden to autonomic aging, but direct human data is limited gap/needs-human-replication
deregulated-nutrient-sensingMetabolic syndrome and insulin resistance are associated with reduced HRV; AMPK/mTOR dysregulation in autonomic neurons hypothesized but not mechanistically established in humans gap/no-mechanism

HRV as a Personal Longitudinal Biomarker

HRV is the most informative continuous biomarker available from consumer wearables for tracking autonomic aging:

  • Tracking frequency: Overnight RMSSD from Oura, Garmin, Polar H10, Whoop, Apple Watch; daily estimates are practical for longitudinal trend-monitoring
  • Personal baselines are essential: absolute RMSSD values vary 3–5-fold between individuals; the meaningful metric is deviation from one’s own baseline, not cross-individual comparison to population norms
  • Target range for aging context: Maintaining or increasing one’s 30-day rolling average RMSSD is a meaningful fitness signal; any sustained >10–15% drop below personal baseline warrants investigation (overtraining, illness, poor sleep, stress)
  • Morning readiness: Low-HRV mornings (relative to baseline) predict impaired exercise-performance capacity the same day — useful for training load decisions
  • Goodhart limitation: RMSSD is moderately gameable via slow breathing (the metric rises steeply during paced-breathing practice), which can inflate wearable-reported overnight RMSSD if slow-breathing exercises occur close to sleep. Standardize measurement conditions.
  • Clinically meaningful change: A sustained elevation of RMSSD (>10% above 30-day rolling mean) following 4–12 weeks of aerobic training is a measurable adaptation signal

Limitations and Gaps

  1. MR null for all-cause mortality — the robust observational HR of ~1.5–2× comparing lowest HRV quartile to others is not supported by genetic causal inference 8. Confounding by fitness, disease burden, and metabolic health is substantial. HRV should be interpreted as an integrative fitness-autonomic marker and risk stratifier, not a causally independent driver of mortality. gap/contradictory-evidence

  2. Measurement standardization — HRV is highly sensitive to pre-measurement conditions (posture, breathing rate, time of day, caffeine, acute exercise, illness, temperature). Cross-study and cross-device comparisons require caution. Consumer wearable RMSSD is directionally valid for trend monitoring but not clinically equivalent to supine 5-min ECG. gap/dose-response-unclear

  3. Test-retest reliability — short-term HRV (5-min) has moderate-to-good intra-individual reproducibility (ICC ~0.70–0.85 in controlled conditions), but day-to-day biological variability is large; single measurements should not be over-interpreted. Population-level ICC data for wearable overnight HRV is incompletely characterized. gap/needs-replication

  4. LF/HF ratio controversy — the LF/HF ratio is frequently reported as a sympathovagal balance index but is confounded by breathing rate, posture, and mental state; Task Force guidance notes this limitation; it should not be used as a reliable sympathetic activity index 5

  5. Sex and age interactions — women generally have higher HF power than age-matched men through much of adult life; intervention effects on HRV may differ by sex. This is insufficiently characterized in RCTs of aging-specific populations. gap/needs-replication

  6. Cholinergic anti-inflammatory pathway causality — while the mechanistic logic (vagal tone → α7nAChR → NF-κB suppression) is well-established in rodent models, direct human interventional evidence that raising HRV via exercise or slow breathing reduces inflammatory markers through the CAP specifically (rather than through other exercise-induced pathways) is limited. gap/needs-human-replication

  7. Very low HRV in the oldest-old — at RMSSD values approaching 10–15 ms (common in octogenarians), the signal-to-noise ratio of consumer devices may be insufficient for reliable trend monitoring; clinical-grade short-lead ECG is preferred for this age group. gap/dose-response-unclear

Cross-References

  • resting-heart-rate-biomarker — sibling vital-sign biomarker; RHR and HRV are inversely correlated within individuals and share autonomic determinants; RHR reflects chronotropic drive, HRV reflects autonomic flexibility
  • vo2max-biomarker — fitness biomarker correlated with HRV; VO₂max and HRV both reflect cardiorespiratory fitness and independently predict mortality
  • nervous-system — autonomic nervous system page; central origin of vagal outflow
  • cardiovascular-system — the cardiac-autonomic effector system
  • chronic-inflammation — inflammaging link via the cholinergic anti-inflammatory pathway
  • exercise — primary intervention for HRV augmentation; aerobic training is the best-validated modality
  • sleep — sleep quality is a major acute modulator of HRV; chronic sleep restriction suppresses baseline RMSSD

Footnotes

Footnotes

  1. doi:10.1161/01.cir.90.2.878 · Tsuji H, Venditti FJ Jr, Manders ES, Evans JC, Larson MG, Feldman CL, Levy D · Circulation 1994;90(2):878–883 · prospective cohort (Framingham Heart Study) · n=736 elderly community-dwelling subjects (mean age 72±6 years); 4-yr follow-up · reduced HRV (multiple measures; low-frequency power was strongest independent predictor in multivariate analysis) associated with significantly increased all-cause mortality; foundational cohort study for HRV-mortality link · model: humans (community-dwelling elderly) · PMID: 8044959 ↩ ↩2

  2. doi:10.1161/01.cir.102.11.1239 · Dekker JM, Crow RS, Folsom AR, Hannan PJ, Liao D, Swenne CA, Schouten EG · Circulation 2000;102(11):1239–1244 · prospective cohort — case-cohort design (ARIC Study) · parent cohort n=14,672 adults aged 45–65; HRV measured in random subsample of ~900 + all incident CHD cases (n=395) and deaths (n=443) through 1993; 2-min rhythm-strip SDNN; lowest vs. intermediate SDNN tertile: all-cause RR 1.50–1.51, CVD mortality RR 1.98–2.10 · low SDNN predicted CHD and all-cause mortality independent of risk factors; risk could not be attributed to disease at baseline · model: humans (community-dwelling middle-aged adults) · PMID: 10982537 ↩ ↩2

  3. doi:10.1016/j.neubiorev.2022.104907 · Jarczok MN, Weimer K, Braun C, Williams DP, Thayer JF, Gündel HO, Balint EM · Neurosci Biobehav Rev 2022;143:104907 · systematic review + meta-analysis · 32 studies (37 samples); n=38,008 participants · 5-min RMSSD lowest quartile vs others: combined HR 1.56 (95% CI 1.32–1.85); lower HRV predicted higher mortality across all ages, sexes, continents, and populations · model: humans (mixed healthy + patient populations) · PMID: 36243195 ↩ ↩2

  4. doi:10.1016/j.arr.2024.102521 · Olivieri F, Biscetti L, Pimpini L, Pelliccioni G, Sabbatinelli J, Giunta S · Ageing Res Rev 2024;101:102521 · review · autonomic nervous system imbalance (sympathetic excess + vagal insufficiency) as a biomarker of aging and inflammaging; HRV as the practical readout of ANS imbalance; cholinergic anti-inflammatory pathway mechanism; advocates for HRV as an accessible aging biomarker · model: humans · PMID: 39341508 ↩ ↩2 ↩3 ↩4

  5. doi:10.1161/01.cir.93.5.1043 · Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology · Circulation 1996;93(5):1043–1065 · consensus standards document · n=not applicable (standards and recommendations) · design: expert committee review · canonical definitions of SDNN, RMSSD, pNN50, HF, LF, LF/HF; defines measurement conditions and clinical interpretation framework · PMID: 8598068 ↩ ↩2

  6. doi:10.3389/fpubh.2017.00258 · Shaffer F, Ginsberg JP · Front Public Health 2017;5:258 · review · n=not applicable · widely-cited (6,200+ citations) practical overview of all HRV metrics, normative values, and clinical context · model: humans · PMID: 29034226 ↩ ↩2

  7. doi:10.1111/j.1540-8159.2010.02841.x · Nunan D, Sandercock GR, Brodie DA · Pacing Clin Electrophysiol 2010;33(11):1407–1417 · systematic review (quantitative) · n=21 studies; provides normative RMSSD/SDNN values for short-term (5 min) HRV in healthy adults across age groups; substantial inter-individual variability documented · model: humans (healthy adults) · PMID: 20663071 ↩ ↩2

  8. doi:10.1038/s42003-023-05376-y · Tegegne BS, Said MA, Ani A, van Roon AM, Shah S, de Geus EJC, van der Harst P, Riese H, Nolte IM, Snieder H · Commun Biol 2023;6:1013 · GWAS + prospective cohort (UK Biobank) · GWAS n=46,075 European ancestry; prospective mortality analysis n=54,312 (median follow-up 6.99–8.14 yr; 1,548 deaths, 2.9%); genetic risk score analysis n=412,891 · 23 genome-wide significant variants in 16 loci (17 independent; 8 novel) for HRV; phenotypic HRV associated with all-cause mortality (lnRMSSD HR 1.19, 95% CI 1.10–1.28; lnSDNN HR 1.32, 95% CI 1.23–1.43); genetically predicted HRV NOT associated with all-cause or CVD mortality; MR null for mortality; genetic predisposition alone does not explain phenotypic mortality link · model: humans · PMID: 37803156 ↩ ↩2 ↩3

  9. doi:10.1111/eci.14085 · Zhao Y, Yu H, Gong A, Zhang S, Xiao B · Eur J Clin Invest 2024;54(1):e14085 · Mendelian randomization (two-sample; IVW primary) · GWAS instruments for SDNN, RMSSD, pvRSA/HF against cardiovascular outcomes · genetically predicted pvRSA/HF associated with cardiac arrest: OR 2.02 (95% CI 1.25–3.28; p=0.004); no association with hypertension, heart failure, MI, or arrhythmia; no heterogeneity or pleiotropy detected · model: humans · PMID: 37641564 ↩ ↩2

  10. doi:10.1007/s00392-022-02072-5 · Geurts S, Tilly MJ, Arshi B, Stricker BHC, Kors JA, Deckers JW, de Groot NMS, Ikram MA, Kavousi M · Clin Res Cardiol 2023;112(6):747–758 · longitudinal cohort + two-sample Mendelian randomization (Rotterdam Study); n=12,334; median follow-up 9.4 years; 1,302 incident AF cases · observational: higher SDNN (HR 1.24, 95% CI 1.04–1.47) and higher RMSSD (HR 1.33, 95% CI 1.13–1.54) associated with increased incident AF, especially in women; MR: supported causal association — genetically determined SDNN (IVW OR 1.60, 95% CI 1.27–2.02, p=8.36×10⁻⁵) and RMSSD (IVW OR 1.56, 95% CI 1.31–1.86, p=6.32×10⁻⁷) both associated with increased AF; no heterogeneity or pleiotropy; conclusion: modulating HRV may reduce AF risk, particularly in women · model: humans (population-based) · PMID: 35962833 ↩ ↩2

  11. doi:10.1371/journal.pone.0299793 · El-Malahi O, Mohajeri D, Mincu R, Bäuerle A, Rothenaicher K, Knuschke R, Rammos C, Rassaf T, Lortz J · PLoS One 2024;19(4):e0299793 · systematic review + meta-analysis (RCTs and non-RCTs in CVD patients with CHF, CAD, PAD, or ACS/MI) · n=19 studies with accessible results from 22 reports; 16 studies in the meta-analysis · overall short-term pooled: SDNN significant (SMD 0.30, p=0.01); RMSSD overall not significant (SMD 0.32, p=0.15); CHF subgroup: RMSSD (p=0.01) and SDNN (p=0.02) significant; 24-h LF/HF ratio improved (p=0.05) · model: humans with established cardiovascular disease · PMID: 38578755 ↩

  12. doi:10.1016/j.neubiorev.2022.104711 · Laborde S, Allen MS, Borges U, Dosseville F, Hosang TJ, Iskra M, Mosley E, Salvotti C, Spolverato L, Zammit N, Javelle F · Neurosci Biobehav Rev 2022;138:104711 · systematic review + meta-analysis · 223 studies (172 during session; 16 immediate post-session; 49 multi-session) · consistent increases in vagally-mediated HRV with voluntary slow breathing during sessions, immediately after, and with sustained multi-session practice; supports slow breathing as accessible intervention to augment parasympathetic tone · model: humans · PMID: 35623448 ↩

Graph View

Backlinks